News
News
Current position:News > News
News
GLP1R:Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
2025-07-31
OX40/OX40L: Broadly Involved in Inflammation, Autoimmunity, and Cancer
OX40 is gaining momentum as a high-value target in next-generation immunomodulation.

With its pivotal role in T cell co-stimulation and involvement in both oncology and autoimmune diseases, OX40 has attracted increasing clinical attention. Multiple assets targeting this pathway are advancing through late-stage trials, marking a new wave of immune-focused therapeutic strategies.
2025-07-24
CLDN18.2×4-1BB:I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
2025-07-18
CD276 Heats Up: The Race for the Next Blockbuster ADC
2025-07-17
PD-1/VEGF: Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports
2025-07-10
IL-11:AbbVie to Acquire Capstan Therapeutics,Further Strengthening Commitment to Transforming Patient Care in Immunology
2025-07-03
What’s Next After GLP-1? ActRII Ignites a New Wave of High-Quality Weight Loss
2025-07-01
TROP2:Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
2025-06-25
After the GLP-1, where is the next breakthrough in weight-loss drugs?
With global GLP-1 drug sales exceeding $50B in 2024, the weight-loss drug market is evolving fast — but the future goes far beyond single-target therapies.

From GLP-1 multi-target combinations to emerging mechanisms like amylin, ACSL5, and ActRII, the next generation of treatments is shifting toward metabolic optimization, muscle preservation, and sustainable weight loss.
2025-06-19
Amylin:Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial
2025-06-18
First 1 2 3 4 5 Last
Total 5 Page
Jump
Current position:News > News
classify
News
GLP1R:Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
2025-07-31
OX40/OX40L: Broadly Involved in Inflammation, Autoimmunity, and Cancer
OX40 is gaining momentum as a high-value target in next-generation immunomodulation.

With its pivotal role in T cell co-stimulation and involvement in both oncology and autoimmune diseases, OX40 has attracted increasing clinical attention. Multiple assets targeting this pathway are advancing through late-stage trials, marking a new wave of immune-focused therapeutic strategies.
2025-07-24
CLDN18.2×4-1BB:I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
2025-07-18
CD276 Heats Up: The Race for the Next Blockbuster ADC
2025-07-17
PD-1/VEGF: Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports
2025-07-10
IL-11:AbbVie to Acquire Capstan Therapeutics,Further Strengthening Commitment to Transforming Patient Care in Immunology
2025-07-03
What’s Next After GLP-1? ActRII Ignites a New Wave of High-Quality Weight Loss
2025-07-01
TROP2:Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
2025-06-25
After the GLP-1, where is the next breakthrough in weight-loss drugs?
With global GLP-1 drug sales exceeding $50B in 2024, the weight-loss drug market is evolving fast — but the future goes far beyond single-target therapies.

From GLP-1 multi-target combinations to emerging mechanisms like amylin, ACSL5, and ActRII, the next generation of treatments is shifting toward metabolic optimization, muscle preservation, and sustainable weight loss.
2025-06-19
Amylin:Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial
2025-06-18
MORE
Message consultation
reset
submit
Service
Message
Message consultation
reset
submit